The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Amgen
Stock and Other Ownership Interests - Amgen
Early tumor shrinkage (ETS) and depth of response (DpR) in wild-type (WT) RAS tumors from the phase III trial of panitumumab (pmab) plus best supportive care (BSC) versus BSC in chemorefractory metastatic colorectal cancer (mCRC).
 
Tae Won Kim
Consulting or Advisory Role - Amgen; Bayer; Roche
 
Anneli Elme
Honoraria - Lilly; Roche
Consulting or Advisory Role - Amgen; Roche
Travel, Accommodations, Expenses - Amgen; Roche
 
Joon Ho Park
Honoraria - Celgene
Consulting or Advisory Role - Celgene; Taiho Pharmaceutical
Research Funding - AstraZeneca; Celgene
 
Anghel Adrian Udrea
Honoraria - AstraZeneca; Bristol-Myers Squibb; Lilly; Novartis; PFIZER; Roche; Sandoz; Teva
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Teva
Travel, Accommodations, Expenses - Astellas Pharma; Janssen; PFIZER; Teva
 
Nebojsa S. Manojlovic
No Relationships to Disclose
 
Xuesong Guan
No Relationships to Disclose
 
A. Scott Jung
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Eduard Vrdoljak
Honoraria - AstraZeneca; Pfizer; Roche
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Merck; Novartis; Pfizer; Roche
Research Funding - Roche
Travel, Accommodations, Expenses - Pfizer; Roche